Simpson Thacher represented the initial purchasers, led by J.P. Morgan Securities LLC, in connection with an upsized debut debt offering by Syneos Health, Inc. (“Syneos Health”) of $600 million aggregate principal amount of 3.625% Senior Notes due 2029 pursuant to Rule 144A and Regulation S. The Notes are guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Syneos Health’s subsidiaries. The offering was upsized from $500 million to $600 million.
Syneos Health is a leading global biopharmaceutical solutions organization providing a full suite of clinical and commercial services to customers in the biopharmaceutical, biotechnology, and medical device industries. Syneos Health offers both stand-alone and integrated biopharmaceutical product development solutions through its Contract Research Organization and Contract Commercial Organization, ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products, with the goal of increasing the likelihood of regulatory approval and commercial success.
The Simpson Thacher team included Roxane Reardon, David Azarkh, Sean Dougherty, Kyle Schwab, Pia Figuerola and Gianna Ceophas (Capital Markets); Jonathan Cantor and Scott Grundei (Tax); Vanessa Burrows (Healthcare); Lori Lesser and Bobbie Burrows (IP); and Jennie Getsin (Blue Sky).